"Individual Patient Expanded Access IND Using HB-adMSCs to Treat of Spinal Cord Injury"
"Individual Patient Expanded Access IND Using HB-adMSCs to Treat of Spinal Cord Injury"
This Individual Patient Expanded Access IND has been created per the request of a 19-year-old
 man who has been diagnosed with Spinal Cord Injury.
Subject is a 19-year-old male who fell approximately 50 feet onto his back during a skiing
 accident. He suffered traumatic anterolisthesis at T10-11 with associated spinal cord
 transection and obliteration of the central canal. He and his family are requesting this
 Individual Patient Expanded Access IND with the purpose of possible restoration of nerve
 transmission and restoring sensation in his lower body using intravenous autologous adipose
 derived mesenchymal stem cells. This study will give 14 infusions of 200 million HB-adMSC's
 over a 52 week period.
Inclusion Criteria:

 1. Adult individual 18 years of age or older.

 2. Cognitively intact and capable of giving informed consent.

 3. Clinical diagnosis of Traumatic Spinal Cord Injury.

 4. Subject has mesenchymal stem cells banked at Hope Biosciences.

 5. The patient accepts to receive treatment and to comply with follow-up visits.

 Exclusion Criteria:

 1. Clinically significant, uncontrolled cardiovascular, lung, renal, hepatic, or
 endocrine disease or any other acute or chronic medical condition that, in the opinion
 of the investigator may increase the risks associated with study participation.

 2. Active Alcohol or Drug addiction.

 3. Participation in concurrent interventional research studies during this study.

 4. Severe organ failure (heart, kidney or liver), confirmed by additional tests or
 medical history.

 5. Unwillingness to return for follow-up visits.